François Laliberté
Montreal
Education
M.A. and B.A., economics, Université de Sherbrooke
Summary of Experience
Mr. Laliberté specializes in biostatistics and the economics of health outcomes research. He investigates multiple facets of health research, including safety, cost of illness, resource utilization, adherence to therapies, cost effectiveness, and treatment outcomes. Mr. Laliberté’s varied research has examined numerous forms of cancers, respiratory diseases, chronic kidney disease, diabetes mellitus, atrial fibrillation, heart failure, and venous thromboembolism. He has additional expertise in the retrospective database analysis of claims and electronic medical records, and in retrospective medical chart review studies and clinical trial data analyses. Mr. Laliberté’s research has yielded important findings in his field which have been presented at the conferences of the American Heart Association (AHA) and the American Society of Clinical Oncology (ASCO), among others. He has published numerous papers in medical journals, including articles in CHEST and the American Journal of Hematology.
Selected Cases
Selected Publishing
-
Impact of adherence to treatment with inhaled corticosteroids/long-acting β-agonists on asthma outcomes in the United States
Therapeutic Advances in Respiratory Disease, 2022
2022Averell CM, Laliberté F, Germain G, Duh MS, Rousculp MD, MacKnight SD, Slade DJ
-
The real-world health resource use and costs of misdiagnosing bipolar I disorder
Journal of Affective Disorders, 2022
2022McIntyre RS, Laliberté F, Germain G, MacKnight SD, Gillard P, Harrington A
-
Adherence and Persistence to Single-Inhaler Versus Multiple-Inhaler Triple Therapy for Asthma Management
The Journal of Allergy and Clinical Immunology: In Practice, 2022
2022Busse WW, Abbott CB, Germain G, Laliberté F, MacKnight SD, Jung Y, Duh MS, Averell CM
-
Symptom control in patients with asthma using inhaled corticosteroids/long-acting β2-agonists (fluticasone furoate/vilanterol or budesonide/formoterol) in the US: a retrospective matched cohort study
Journal of Asthma, 2022
2022Averell CM, Laliberté F, Germain G, Duh MS, Lima R, Mahendran M, Slade DJ
-
Real-World Healthcare Resource Utilization in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the USA
Targeted Oncology, 2021
2021Laliberté F, Raut M, Yang X, Germain G, Nahar A, Desai KD, MacKnight SD, Sen SS, Duh MS
-
Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP Inhibitors
Advances in Therapy, 2021
2021Shore ND, Laliberté F, Ionesco-Ittu R, Yang L, Mahendran M, Lejeune D, Yu LH, Burgents J, Duh MS, Ghate SR
-
Umeclidinium/Vilanterol Compared with Fluticasone Propionate/Salmeterol, Budesonide/Formoterol, and Tiotropium as Initial Maintenance Therapy in Patients with COPD Who Have High Costs and Comorbidities
International Journal of Chronic Obstructive Pulmonary Disease, 2021
2021Kalhan R, Slade D, Ray R, Moretz C, Germain G, Laliberté F, Shen Q, Duh MS, MacKnight SD, Hahn B
-
Real-World Characteristics, Treatment Patterns, Health Care Resource Use, and Costs of Patients with Diffuse Large B-Cell Lymphoma in the U.S.
The Oncologist, 2021
2021Yang X, Laliberté F, Germain G, Raut M, Duh MS, Sen SS, Lejeune D, Desai K, Armand P
-
Real-world genetic testing patterns in metastatic castration-resistant prostate cancer
Future Oncology, 2021
2021Shore N, Ionescu-Ittu R, Yang L, Laliberté F, Mahendran M, Lejeune D, Yu L, Burgents J, Duh MS, Ghate SR
-
Real-world impact of antiepileptic drug combinations with versus without perampanel on healthcare resource utilization in patients with epilepsy in the United States
Epilepsy & Behavior, 2021
2021Laliberté F, Duh MS, Barghout V, Germain G, Frech F, Plauschinat C, Lejeune D, Malhotra M, Faught E
-
Healthcare resource utilization and costs of major atherothrombotic vascular events among patients with peripheral artery disease after revascularization
Journal of Medical Economics, 2021
2021Desai U, Kharat A, Hess CN, Milentijevic D, Laliberté F, Zuckerman P, Benson J, Lefebvre P, Hiatt WR, Bonaca MP
-
Incidence of Major Atherothrombotic Vascular Events among Patients with Peripheral Artery Disease after Revascularization
Annals of Vascular Surgery, 2021
2021Desai U, Kharat A, Hess CN, Milentijevic D, Laliberté F, Zuckerman P, Benson J, Lefebvre P, Hiatt WR, Bonaca MP
-
Persistence to hypomethylating agents and clinical and economic outcomes among patients with myelodysplastic syndromes
Journal of Hematology, 2021
2021Cheng WY, Satija A, Cheung HC, Hill K, Wert T, Laliberté F, Lefebvre P
-
Treatment patterns, healthcare resource utilization, and costs of patients diagnosed with primary mediastinal B-cell lymphoma in the United States
Journal of Medical Economics, 2021
2021Yang X, Laliberté F, Germain G, Raut M, Duh MS, Sen SS, Lejeune D, Desai K, Armand P
-
Time-to-first exacerbation, adherence, and medical costs among US patients receiving umeclidinium/vilanterol or tiotropium as initial maintenance therapy for chronic obstructive pulmonary disease: a retrospective cohort study
BMC Pulmonary Medicine, 2021
2021Slade D, Ray R, Moretz C, Germain G, Laliberté L, Shen Q, Duh MS, Mahendran M, Hahn B
-
Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP Inhibitors
Advances in Therapy, 2021
2021Shore ND, Laliberté F, Ionescu-Ittu R, Yang L, Mahendran M, Lejeune D, Yu LH, Burgents J, Duh MS, Ghate SR
-
Beyond Frontline Therapy with Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer: A Real-World US Study
Clinical Genitourinary Cancer, 2021
2021Shore ND, Ionescu-Ittu R, Laliberté F, Yang L, Lejeune D, Yu L, Duh MS, Mahendran M, Kim J, Ghate SR
-
EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors
BMC Cancer, 2020
2020Chiang AC, Fernandes AW, Pavilack M, Wu JW, Laliberté F, Duh MS, Chehab N, Subramanian J
-
Direct, Absenteeism, and Disability Cost Burden of Obesity Among Privately Insured Employees: A Comparison of Healthcare Industry Versus Other Major Industries in the United States
Journal of Occupational and Environmental Medicine, 2020
2020Ramasamy A, Laliberté F, Aktavoukian SA, Lejeune D, DerSarkissian M, Cavanaugh C, Smolarz BG, Ganguly R, Duh MS
-
Real-World Adherence in Patients with Metastatic Colorectal Cancer Treated with Trifluridine plus Tipiracil or Regorafenib
Oncologist, 2020
2020Patel AK, Barghout V, Yenikomshian MA, Germain G, Jacques P, Laliberté F, Duh MS
-
Healthcare resource utilization and costs associated with venous thromboembolism recurrence in patients with cancer
Journal of Medical Economics, 2020
2020Khorana AA, McCrae KR, Milentijevic D, Laliberté F, Lejeune D, Crivera C, Lefebvre P
-
Cancer associated thrombosis and mortality in patients with cancer stratified by khorana score risk levels
Cancer Medicine, 2020
2020Khorana AA, Kuderer NM, McCrae K, Milentijevic D, Germain G, Laliberté F, MacKnight SD, Lefebvre P, Lyman GH, Streiff MB
-
Stage III melanoma incidence and impact of transitioning to the 8th AJCC staging system: a US population-based study
Future Oncology. 2019 Feb;15(4):359-370
2019Tarhini A, Ghate S, Ionescu-Ittu R, Shi S, Nakasato A, Ndife B, Laliberté F, Burne R, Duh MS
-
The risk of recurrent VTE and major bleeding in a commercially-insured population of cancer patients treated with anticoagulation
American Journal of Hematology. 2019 Feb;94(2):E58-E61.
2019Khorana AA, McCrae K, Milentijevic D, McCormick N, Laliberté F, Crivera C, Lefebvre P, Lejeune D, Rozjabek H, Schein J, Streiff MB
-
Direct and Indirect Cost of Obesity Among the Privately Insured in the United States: A Focus on the Impact by Type of Industry
Journal of Occupational and Environmental Medicine: November 2019 - Volume 61 - Issue 11
2019Ramasamy A, Laliberté F, Aktavoukian S, Lejeune D, DerSarkissian M, Cavanaugh C, Smolarz BG, Ganguly R, Duh MS
-
The rate of occurrence, healthcare resource use and costs of adverse events among metastatic non-small cell lung cancer patients treated with first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors
Lung Cancer, 2019
2019Subramanian J, Fernandes AW, Laliberté F, Pavilack M, DerSarkissian M, Duh MS
-
Healthcare resource utilization and costs associated with venous thromboembolism in cancer patients treated with anticoagulants
Journal of Medical Economics, 2019
2019Streiff S, Milentijevic D, McCrae KR, Laliberté F, Lejeune D, Lefebvre P, Schein J, Khorana AA
-
Healthcare costs of stroke and major bleeding in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants
Journal of Medical Economics, 2019
2019Rozjabek HM, Coleman CI, Ashton V, Laliberté F, Oyefesobi P, Lejeune D, Germain G, Schein JR, Yuan Z, Lefebvre P, Peterson ED
-
Modeling the impact of real-world adherence to once-daily (QD) versus twice-daily (BID) non-vitamin K antagonist oral anticoagulants on stroke and major bleeding events among non-valvular atrial fibrillation patients
Current Medical Research and Opinion, 2019
2019McHorney CA, Peterson ED, Ashton V, Laliberté F, Crivera C, Germain G, Sheikh N, Schein J, Lefebvre P
-
Cost Implications of Anticoagulation Strategies After Percutaneous Coronary Intervention Among Patients With Atrial Fibrillation (A PIONEER-AF PCI Analysis)
The American Journal of Cardiology, 2019
2019Korjian S, Daaboul Y, Laliberté F, Zhao Q, Mehran R, Bode C, Halperin J, Verheugt FWA, Lip GYH, Cohen M, Peterson ED, Fox KAA, Gibson CM, Pinto DS, PIONEER AF-PCI Investigators
-
Healthcare resource utilization and costs of adverse events among patients with metastatic urothelial cancer in USA
Future Oncology, 2019
2019Grivas P, DerSarkissian M, Shenolikar R, Laliberté F, Doleh Y, Duh MS
-
Medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a USA commercially insured population
International Journal of Chronic Obstructive Pulmonary Disease, 2019
2019Bogart M, Stanford RH, Laliberté F, Germain G, Wu JW, Duh MS
-
Medication adherence in patients with asthma using once-daily versus twice-daily ICS/LABAs
Journal of Asthma, 2019
2019Averell CM, Stanford RH, Laliberté F, Wu JW, Germain G, Duh MS
-
Characterizing Real-World Use Of Tiotropium In Asthma In The USA
Journal of Asthma and Allergy, 2019
2019Averell CM, Laliberté F, Duh MS, Wu JW, Germain G, Faison S
-
Implications of stroke and bleeding risk scores and comorbidities on episode-based bundled payments for patients with nonvalvular atrial fibrillation
Current Medical Research and Opinion. 01 Feb 2018;34(2):275-284
2018Kaatz S, Coleman CI, Bookhart B, Laliberté F, Nelson WW, Brown K, Martin S, Schein J, Lefebvre P
-
Cost comparison of continued anticoagulation with rivaroxaban versus placebo based on the 1-year EINSTEIN-Extension trial efficacy and safety results
Journal of Medical Economics. 2018 Jun;21(6):587-594
2018Wells PS, Lensing AWA, Haskell L, Levitan B, Laliberté F, Durkin M, Ashton V, Xiao Y, Crivera C, Lejeune D, Schein J, Lefebvre P
-
Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer
American Journal of Hematology. May 2018;93(5):664-671
2018Streiff MB1, Milentijevic D, McCrae K, Yannicelli D, Fortier J, Nelson WW, Laliberté F, Crivera C, Lefebvre P, Schein J, Khorana AA
-
Evaluation of clinical outcomes among nonvalvular atrial fibrillation patients treated with rivaroxaban or warfarin, stratified by renal function
Clinical Nephrology. 01 May 2018;89(5):314-329
2018Weir MR, Haskell L, Berger JS, Ashton V, Laliberté F, Crivera C, Brown K, Lefebvre P, Schein J
-
Health-care Cost Impact of Continued Anticoagulation With Rivaroxaban vs Aspirin for Prevention of Recurrent Symptomatic VTE in the EINSTEIN-CHOICE Trial Population
CHEST Journal. 2018 Dec; 154(6):1371–1378
2018 -
Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer
American Journal of Hematology. Feb 2018; 93(3)
2018Streiff M, Milentijevic D, McCrae K, Yannicelli D, Fortier J, Nelson W, Laliberté F, Crivera C, Lefebvre P, Schein J, Khorana A
-
Adherence to rivaroxaban versus apixaban among patients with non-valvular atrial fibrillation: Analysis of overall population and subgroups of prior oral anticoagulant users
PLOS One. 2018 Apr 5;13(4):e0194099
2018McHorney CA, Crivera C, Laliberté F, Germain G, Wynant W, Lefebvre P
-
CMS hospital readmission reduction program and anticoagulants received following a total hip and knee arthroplasty discharge
Current Medical Research and Opinion. 2018 Nov;34(11):1967-1974
2018Laliberté F, Coleman CI, Bookhart B, Schein J, Martin S, Wynant W, Xiao Y, Lefebvre P, Kaatz S
-
Healthcare resource utilization in patients with metastatic melanoma receiving first-line therapy with dabrafenib + trametinib versus nivolumab or pembrolizumab monotherapy
Current Medical Research and Opinion. 2018 Dec;34(12):2169-2176
2018Ghate SR, Ionescu-Ittu R, Burne R, Ndife B, Laliberté F, Nakasato A, Duh MS
-
Patterns of treatment and BRAF testing with immune checkpoint inhibitors and targeted therapy in patients with metastatic melanoma presumed to be BRAF positive
Melanoma Research, October 9, 2018
2018Ghate S, Ionescu-Ittu R, Burne R, Ndife B, Laliberté F, Nakasato A, Duh MS
-
The risk of recurrent VTE and major bleeding in a commercially‐insured population of cancer patients treated with anticoagulation
American Journal of Hematology, November 25, 2018
2018 -
Importance of balancing follow-up time and impact of oral-anticoagulant users' selection when evaluating medication adherence in atrial fibrillation patients treated with rivaroxaban and apixaban
Current Medical Research and Opinion. Jun 2017;33(6):1033-1043
2017Coleman C, Yuan Z, Schein J, Crivera C, Ashton V, Laliberté F, Lefebvre P, Peterson ED
-
Health care resource utilization before and after perampanel initiation among patients with epilepsy in the United States
Epilepsia. Jul 25 2017
2017Faught E, Laliberté F, Wang Z, Barghout V, Haider B, Lejeune D, Germain G, Choi J, Wagh A, Duh MS
-
Risk for Venous Thromboembolism Recurrence Among Rivaroxaban-treated Patients Who Continued Versus Discontinued Therapy: Analyses Among Patients with VTE
Clinical Therapeutics. 01 Jul 2017;39(7):1396-1408
2017Khorana AA, Berger JS, Wells PS, Seheult R, Ashton V, Laliberté F, Crivera C, Lejeune D, Schein J, Wildgoose P, Lefebvre P, Kaatz S
-
Stroke risk reduction outweighed bleeding risk increase from vitamin K antagonist treatment among nonvalvular atrial fibrillation patients with high stroke risk and low bleeding risk
Current Medical Research and Opinion. Apr 2017;33(4):631-638
2017Nelson WW, Laliberté F, Patel AA, Germain G, Pilon D, McCormick N, Lefebvre P
-
Impact of renal function on ischemic stroke and major bleeding rates in nonvalvular atrial fibrillation patients treated with warfarin or rivaroxaban: a retrospective cohort study using real-world evi
Current Medical Research and Opinion. 03 Oct 2017;33(10):1891-1900
2017Weir MR, Berger JS, Ashton V, Laliberté F, Brown K, Lefebvre P, Schein J
-
A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on longacting mono-
International Journal of COPD. 21 Jun 2017;12:1825-1836
2017Mapel D, Laliberté F, Roberts MH, Sama SR, Sundaresan D, Pilon D, Lefebvre P, Duh MS, Patel J
-
Clinical outcomes of prolonged anticoagulation with rivaroxaban after unprovoked venous thromboembolism
Research and Practice in Thrombosis and Haemostasis. 2017 Nov 15;2(1):58-68
2017Berger JS, Seheult R, Laliberté F, Crivera C, Lejeune D, Xiao Y, Schein J, Lefebvre P, Kaatz S
-
Venous thromboembolism and cardiovascular disease complications in menopausal women using transdermal versus oral estrogen therapy
Menopause, 2016 06; 23(6): 600-610
2016Simon JA, Laliberte F, Duh MS, Pilon D, Kahler KH, Nyirady J, Davis PJ, Lefebvre P.
-
Retrospective analysis of the impact of increasing access to long acting reversible contraceptives in a commercially insured population
Reproductive Health, 2016 13(1): 96. e-pub ahead of print 2016/08/24
2016Law A, Pilon D, Lynen R, Laliberte F, Gozalo L, Lefebvre P, Duh MS.
-
Prasugrel vs. clopidogrel in acute coronary syndrome patients treated with prasugrel
Journal of Clinical Pharmacology & Therapeutics, December 2014, Vol. 39, No. 6
2014Olson WH, Ma YW, Laliberte F, Lefebvre P, Crivera C, Schein JR, Fields LE, Dea K, Germain G, Lynch SM
-
Hospital length of stay of nonvalvular atrial fibrillation
Hospital Practice, August 2014, Vol. 42, No. 3
2014Laliberte F, Pilon D, Raut MK, Nelson WW, Olson WH, Germain G, Schein JR, Lefebvre P
-
Is rivaroxaban associated with lower inpatient costs compared to warfarin among patients with non-valvular atrial fibrillation?
Current Medical Research & Opinion, August 2014, Vol. 30, No. 8
2014Laliberte F, Pilon D, Raut MK, Nelson WW, Olson WH, Germain G, Schein JR, Lefebvre P
-
Weekly risk of venous thromboembolism recurrence in patients receiving oral anticoagulants
Current Medical Research & Opinion, August 2014, Vol. 30, No. 8
2014Laliberte F, Coleman CI, Bookhart B, Lefebvre P, Cloutier M, Damaraju CV, Schein JR, Kaatz S
-
Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients
Current Medical Research & Opinion, July 2014, Vol. 30, No. 7
2014Laliberte F, Cloutier M, Nelson WW, Coleman CI, Pilon D, Olson WH, Damaraju CV, Schein JR, Lefebvre P
-
Medicaid spending on contraceptive coverage and pregnancy-related care
Reproductive Health, Mar 3, 2014, Volume 11, No. 1
2014Laliberte F, Lefebvre P, Law A, Duh MS, Pocoski J, Lynen R, Darney P
-
Impact of early versus late systemic lupus erythematosus diagnosis on clinical and economic outcomes
Applied Health Economics and Health Policy, April 2014, Vol. 12, No. 2
2014Oglesby A, Korves C, Laliberte F, Dennis G, Rao S, Suthoff ED, Wei R, Duh MS
-
Hospital length of stay: is rivaroxaban associated with shorter inpatient stay compared to warfarin among patients with non-valvular atrial fibrillation?
Current Medical Research & Opinion, April 2014, Vol. 30, No. 4
2014Laliberte F, Pilon D, Raut MK, Nelson WW, Olson WH, Germain G, Schein JR, Lefebvre P
-
Impact of completing chronic hepatitis C (CHC) treatment on post-therapy healthcare cost
Journal of Medical Economics, December 2014, Vol. 17, No. 12
2014Tandon N, Balart LA, Laliberte F, Pilon D, Lefebvre P, Germain G, Prabhakar A
-
All-cause and disease-related health care costs associated with recurrent venous thromboembolism
Thrombosis and Haemostasis, December 2013, Vol. 110, No. 6
2013Lefebvre P, Laliberte F, Nutescu EA, Duh MS, LaMori J, Bookhart BK, Olson WH, Dea K, Hossou Y, Schein J, Kaatz S
-
Impact of once-daily versus twice-daily dosing frequency on adherence to chronic medications among patients with venous thromboembolism
The Patient, September 2013, Vol. 6, No. 3
2013Laliberte F, Bookhart BK, Nelson WW, Lefebvre P, Schein JR, Rondeau-Leclaire J, Duh MS
-
Direct and indirect cost burden associated with multiple sclerosis relapses: excess costs of persons with MS and their spouse caregivers
Journal of the Neurological Sciences, July 2013, Vol. 330, No. 1-2
2013Parisé H, Laliberte F, Lefebvre P, Duh MS, Kim E, Agashivala N, Abouzaid S, Weinstock-Guttman B
-
All-Cause and Potentially Disease-Related Health Care Costs Associated with Venous Thromboembolism in Commercial, Medicare, and Medicaid Beneficiaries
Journal of Managed Care Pharmacy (June 2012, Vol. 18, Issue 5)
2012Lefebvre P, Laliberté F, Nutescu E, Duh MS, LaMori J, Bookhart B, Olson W, Dea K, Schein J, Kaatz S
-
Does the Route of Administration for Estrogen Hormone Therapy Impact the Risk of Venous Thromboembolism?
Menopause. 2011 Oct;18(10):1052-9.
2011Laliberte F, Dea K, Duh MS, Kahler K, Rolli M, Lefebvre P
-
Risks and cost burden of venous thromboembolism and bleeding for patients undergoing total hip or knee replacement in a managed-care population
J Med Econ. 2011;14(3):324-34.
2011Vekeman F, LaMori J, Laliberte F, Nutescu E, Duh MS, Bookhart B, Schein J, Dea K, Olson W, Lefebvre P
-
Drug utilization and cost considerations of erythropoiesis-stimulating agents in oncology patients receiving chemotherapy
J Med Econ. 2009; 12(1):1-8
2009Vekeman F, McKenzie R, Bookhart B, Laliberté F, Duh M, Piech C, Lefebvre P
-
Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: a managed care perspective
J Manag Care Pharm. 2009; 15(4):312-322
2009Laliberte F, Bookhart B, Vekeman F, Corral M, Duh MS, Bailey R, Piech CT, Lefebvre P
-
Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia
Cancer. 2009; 115(20):4839-48
2009Heaney M, Toy E, Vekeman F, Laliberte F, Dority B, Perlman D, Barghout V, Duh M
-
Drug Utilization and Costs of Erythropoietic-Stimulating Agents in Chronic Kidney Disease Patients Not Receiving Dialysis
Managed Care Interface 2007; Dec:14-19
2007Duh MS, Mody SH, Laliberte F, McKenzie RS, Bookhart B, Lefebvre P
-
Postsurgical treatment landscape and economic burden of locoregional and distant recurrence in patients with operable nonmetastatic melanoma
Melanoma Research. 2018 Dec;28(6):618-628
Tarhini A, Ghate SR, Ionescu-Ittu R, Manceur AM, Ndife B, Jacques P, Laliberté F, Nakasato A, Burne R, Duh MS
News
-
March 2, 2023
-
December 7, 2022
-
October 15, 2021
-
August 18, 2021
-
April 13, 2021
-
February 18, 2020